{"id":7651,"date":"2023-11-14T08:23:51","date_gmt":"2023-11-14T16:23:51","guid":{"rendered":"https:\/\/allocare.caredx.com\/?p=7651"},"modified":"2023-11-14T08:24:02","modified_gmt":"2023-11-14T16:24:02","slug":"mid-stage-win-for-novel-iga-nephropathy-drug","status":"publish","type":"post","link":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2023\/11\/14\/mid-stage-win-for-novel-iga-nephropathy-drug\/","title":{"rendered":"Mid-Stage Win for Novel IgA Nephropathy Drug"},"content":{"rendered":"<span class=\"simplefavorite-button has-count loading\" data-postid=\"7651\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>\n<h2 class=\"wp-block-heading\">\u2014 APRIL-neutralizing antibody sibeprenlimab reduced proteinuria and stabilized eGFR<\/h2>\n\n\n\n<p>By Kristen Monaco<\/p>\n\n\n\n<p>PHILADELPHIA &#8212; An investigational humanized IgG2 monoclonal antibody reduced proteinuria in adults with immunoglobulin A (IgA) nephropathy at high risk for disease progression despite standard treatments, a randomized phase II trial found.<\/p>\n\n\n\n<p>In a dose-dependant manner, intravenous sibeprenlimab led to significantly greater decreases in 24-hour urinary protein-to-creatinine ratio at 12 months compared with placebo, with geometric mean ratio reductions ranging from 47.2% to 62% versus 20%, respectively (<em>P<\/em>&lt;0.001), meeting the trial&#8217;s primary endpoint, reported Mohit Mathur, MD, of drugmaker Visterra in Waltham, Massachusetts. <a href=\"https:\/\/www.medpagetoday.com\/meetingcoverage\/asn\/107120?xid=nl_mpt_confroundup_2023-11-9&amp;mh=0aa0b6037ceefb17d5814920eb48f8e6\">Read the full article<\/a> in MedPage Today.<\/p>\n<span class=\"simplefavorite-button has-count loading\" data-postid=\"7651\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>","protected":false},"excerpt":{"rendered":"<p>Loading \u2014 APRIL-neutralizing antibody sibeprenlimab reduced proteinuria and stabilized eGFR By Kristen Monaco PHILADELPHIA &#8212; An investigational humanized IgG2 monoclonal antibody reduced proteinuria in adults with immunoglobulin A (IgA) nephropathy &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2023\/11\/14\/mid-stage-win-for-novel-iga-nephropathy-drug\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mid-Stage Win for Novel IgA Nephropathy Drug&#8221;<\/span><\/a><\/p>\n","protected":false},"author":208,"featured_media":3832,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":0,"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_tribe_blocks_recurrence_rules":"","_tribe_blocks_recurrence_description":"","_tribe_blocks_recurrence_exclusions":"","_ecp_custom_2":"","footnotes":""},"categories":[45,2,15],"tags":[2449,2451],"post_format":[],"Dislikes":"","Likes":"","simplefavorites_count":"","views":"1282","post_likes_plusCounter":"","post_dislikes_plusCounter":"","acf":[],"_links":{"self":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/7651"}],"collection":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/users\/208"}],"replies":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/comments?post=7651"}],"version-history":[{"count":1,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/7651\/revisions"}],"predecessor-version":[{"id":7652,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/7651\/revisions\/7652"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media\/3832"}],"wp:attachment":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media?parent=7651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/categories?post=7651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/tags?post=7651"},{"taxonomy":"post_format","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/post_format?post=7651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}